<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788931</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589C2114</org_study_id>
    <secondary_id>2007-004788-23</secondary_id>
    <nct_id>NCT00788931</nct_id>
  </id_info>
  <brief_title>A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer</brief_title>
  <official_title>A Phase Ib, Open-label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both&#xD;
      intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel.&#xD;
      The study will evaluate safety and efficacy of the combination in adult female patients with&#xD;
      HER2+ metastatic breast cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of oral panobinostat in combination with trastuzumab and paclitaxel. Determine the maximum tolerated dose of iv LBH in combination with trastuzumab and paclitaxel.</measure>
    <time_frame>At least 21 day cycle for both arms</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability throughout the study for both IV and oral arms to determine the recommended dose for phase ll trials.</measure>
    <time_frame>4 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy in the expansion phase of the trial when the MTD is defined.</measure>
    <time_frame>throughout the study and 4 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HER-2 Positive Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IV LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. panobinostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral panobinostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV LBH589</intervention_name>
    <arm_group_label>IV LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral LBH589</intervention_name>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>IV LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>IV LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 year old&#xD;
&#xD;
          -  Confirmed HER2+ metastatic breast cancer&#xD;
&#xD;
          -  Prior treatment and progression on trastuzumab&#xD;
&#xD;
          -  Patients must have adequate organ functions&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had surgery within last 2 weeks prior to starting the treatment&#xD;
&#xD;
          -  Patients who receive concurrent therapy for brain metastases&#xD;
&#xD;
          -  Impaired heart function or clinically significant heart disease&#xD;
&#xD;
          -  Ongoing diarrhea&#xD;
&#xD;
          -  Liver or renal disease with impaired hepatic or renal functions&#xD;
&#xD;
          -  Concomitant use of any anti-cancer therapy or certain drugs&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients not willing to use an effective method of birth control Other&#xD;
             protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Macerata</city>
        <state>MC</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4342</url>
    <description>Results for LBH589C2114 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>adult-female</keyword>
  <keyword>LBH589</keyword>
  <keyword>HDAC inhibitor</keyword>
  <keyword>panobinostat</keyword>
  <keyword>metastatic breast</keyword>
  <keyword>adult female patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

